Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scient (MLSS) delivers innovative computer-controlled anesthetic systems designed to improve patient comfort in dental and medical procedures. This dedicated news hub provides real-time updates on the company’s technological advancements, regulatory milestones, and strategic partnerships.
Access authoritative information on MLSS’s global expansion across 25+ countries, product innovations like the CompuDent and CompuMed systems, and financial performance. The curated content serves investors and healthcare professionals seeking to monitor the company’s impact on pain management technology.
Key updates include FDA clearances, clinical trial results, partnership announcements with medical institutions, and market penetration strategies. All content is sourced directly from official company communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to MLSS’s latest developments, enabling data-driven insights into its role in advancing precision anesthetic delivery worldwide.
Milestone Scientific (NYSE: MLSS) reported financial results for 2024, showing revenue of $8.6 million, down from $9.8 million in 2023. Despite the revenue decline, the company highlighted positive developments including Medicare reimbursement expansion for its CompuFlo® Epidural System across multiple U.S. states and a Federal Supply Schedule contract.
The company's U.S. e-commerce platform for dental products generated $5.1 million in revenue, up from $4.8 million in 2023. International revenue decreased to $3.4 million. Gross profit was $6.4 million, down from $6.8 million in 2023. Operating loss improved to $6.8 million from $7.1 million, while net loss decreased to $4.7 million ($0.06 per share) from $6.9 million ($0.10 per share) in 2023.
The company ended 2024 with $3.3 million in cash, $5.5 million in working capital, and no debt, while reporting strong Q1 2025 initial performance and positive outlook.
Milestone Scientific (NYSE: MLSS) has announced that InfiniSurg, , a New Jersey-based ambulatory surgery center, has adopted its CompuFlo® Epidural System for clinical practice. The system will be operated by Dr. Roman Kosiborod, DO, who brings over 20 years of experience in interventional pain management and ambulatory anesthesia.
The order was received through Milestone's distributor, Axial Biologics. The CompuFlo® system utilizes Dynamic Pressure Sensing Technology® to precisely identify the epidural space, providing real-time visual and audible feedback during needle placement. This technology aims to reduce complications such as dural puncture while improving procedural efficiency and patient safety.
Milestone Scientific (NYSE: MLSS) announced the commercial implementation of its CompuFlo® Epidural System at Pain Doctors Medical , following a successful evaluation by Dr. Ilana Etelzon. The system, which employs proprietary Dynamic Pressure Sensing Technology®, provides real-time verification of epidural needle placement to enhance patient safety and procedural efficiency.
The implementation follows the recent Medicare price assignment for the CompuFlo® system, which is helping drive broader accessibility across interventional pain management centers. The technology offers real-time feedback for needle placement confirmation, improving procedural accuracy and safety in pain management procedures.
Milestone Scientific (NYSE: MLSS) announced the commercial rollout of its CompuFlo® Epidural System at Advanced Spine and Pain Management, following a successful pilot program with Dr. Varinder Dhillon. The implementation takes place at SurgiCore Montvale, one of 12 SurgiCore centers in the NY/NJ metro area, suggesting potential for network expansion.
The company reports increasing adoption of the system following a recent Medicare price assignment. The CompuFlo® Epidural System, powered by Dynamic Pressure Sensing Technology®, provides real-time feedback for accurate needle placement during epidural procedures, reducing complications associated with traditional techniques.
Dr. Dhillon praised the system's precision and reliability in improving patient care and procedural efficiency. Neal Goldman, Chairman and Interim CEO, highlighted the growing traction within the healthcare community, particularly among pain management clinics nationwide following the Medicare price assignment.
Milestone Scientific (NYSE: MLSS), a developer of computerized drug delivery instruments for painless and precise injections, has announced its participation in The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference. The event will take place on December 11th, 2024 at the New York Athletic Club in New York City.
CEO Arjan Haverhals and Chairman Neal Goldman will represent the company, with Haverhals conducting one-on-one meetings with investors and analysts throughout the conference day. The conference provides emerging growth companies the opportunity to connect with institutional and individual investors in a unique format.
Milestone Scientific has secured Federal Supply Schedule (FSS) approval for its CompuFlo® Epidural System, enabling pre-vetted contractor status with pre-negotiated pricing. The contract has a potential duration of up to 20 years, including extensions. The FSS designation opens significant opportunities within federal healthcare systems, including the Department of Defense, Veterans Affairs, and Indian Health Service. The CompuFlo® system uses patented Dynamic Pressure Sensing Technology® for accurate needle placement during epidural procedures. The contract provides access to the VHA's network of 1,380 facilities serving 9.1 million veterans, the Military Health System's 9.5 million beneficiaries, and the IHS's 687 facilities serving 2.8 million American Indians and Alaska Natives.
Milestone Scientific (NYSE: MLSS) reported a 22% year-over-year revenue increase to $2.5 million in Q3 2024, driven by a 57% rise in international dental sales. The company maintained a strong gross margin of 73%. The growth was supported by their e-commerce platform and expanded global distribution. Their CompuFlo® Epidural System gained traction following Medicare Part B payment rate approval in multiple states. Despite revenue growth, the company reported an operating loss of $(1.5) million. Cash position stood at $4.8 million with working capital of $6.9 million as of September 30, 2024.
Milestone Scientific (NYSE: MLSS) announced that CEO Arjan Haverhals will retire on December 31, 2024. Chairman Neal Goldman will serve as Interim CEO while the company searches for a permanent replacement. Haverhals will remain on the Board and provide consulting services during the transition. The company is retaining an executive search firm to find a permanent CEO who will focus on accelerating the commercialization of the CompuFlo® Epidural System. Under Haverhals' leadership, the company achieved financial stability and secured Medicare Part B Physician payment rates for CompuFlo® across multiple JMAC regions.
Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments for painless and precise injections, has scheduled a conference call for Friday, November 15th, 2024, at 8:30 AM Eastern Time. The call will discuss the company's third quarter 2024 financial results for the period ended September 30, 2024, along with corporate progress and developments. Investors can access the call via telephone or webcast, with an audio replay available through November 29th, 2024.
Milestone Scientific (NYSE: MLSS) announced the commercial rollout of its CompuFlo® Epidural System at Hudson Specialty Care, led by Dr. Elbaz. This expansion follows the recent Medicare Part B payment rate assignment with FCSO and Novitas Solutions under CPT code CPT0777T. The implementation results from Milestone's partnership with Axial Biologics, with additional pilot programs ongoing in New Jersey, Texas, and Florida. The company will showcase the technology at the New York and New Jersey Pain Medicine Congress 2024. The CompuFlo system uses proprietary technology to precisely identify epidural space, enhancing procedure safety and efficiency.
